PMID- 32138533
OWN - NLM
STAT- MEDLINE
DCOM- 20200827
LR  - 20200827
IS  - 1793-6853 (Electronic)
IS  - 0192-415X (Linking)
VI  - 48
IP  - 2
DP  - 2020
TI  - Corydalis saxicola Alkaloids Attenuate Cisplatin-Induced Neuropathic Pain by 
      Reducing Loss of IENF and Blocking TRPV1 Activation.
PG  - 407-428
LID - 10.1142/S0192415X20500214 [doi]
AB  - Chemotherapy-induced peripheral neuropathy (CIPN) is a common complication of 
      cisplatin, which is characterized by intolerable paresthesia, burning, and 
      hyperalgesia, and severely impacts the life quality of patients. However, no 
      clearly potent drug has been found for clinical medication due to its undefined 
      mechanism. Corydalis Saxicola Bunting, a traditional Chinese medicine, has been 
      proven to work well in anti-inflammation, blood circulations improvement, 
      hemostasis, and analgesia. This study was designed to observe the effects of 
      Corydalis saxicola Bunting total alkaloids (CSBTA) on cisplatin-induced 
      neuropathic pain and to explore its potential mechanisms. In this study, the rats 
      received intraperitoneal injection of 2 mg/kg cisplatin twice a week for five 
      weeks. Meanwhile, oral administration of low (30 mg/kg)-, medium (60 mg/kg)- and 
      high (120 mg/kg)-dose CSBTA were given daily for five weeks. By using Von-frey 
      hair, heat radiant and - 80 composite functionC cold acetone, we found that CSBTA could obviously 
      relieve cisplatin-induced mechanical, heat, and cold hyperalgesia. It has been 
      verified that cisplatin-induced peripheral neuropathy is related to 
      intraepidermal nerve fibers loss and activation of inflammation downstream. Our 
      research found that Tumor necrosis factor-alpha (TNF-alpha), Interleukin-1beta 
      (IL-1beta), and Prostaglandin E2 (PGE2) were significantly increased by 10 
      intraperitoneal injections of cisplatin, and such pro-inflammation cytokines 
      could be reduced via CSBTA administration. Besides, in the cisplatin model group, 
      the neuronal structures of dorsal root ganglia (DRG) were severely damaged and 
      the loss of intraepidermal nerve fibers occurred; but in the CSBTA administration 
      groups, all above pathological changes were improved. Moreover, CSBTA could 
      normalize the overexpression levels of p-p38 and Transient receptor potential 
      vanilloid receptor (TRPV1) induced by cisplatin in DRG, trigeminal ganglion (TG), 
      spinal cord, and foot of rats. In summary, we considered that CSBTA exerted its 
      therapeutic effects by ameliorating neuronal damages, improving intraepidermal 
      nerve fiber (IENF) loss, and inhibiting inflammation-induced p38 phosphorylation 
      to block TRPV1 activation. These findings were the first to confirm the analgesic 
      effect of CSBTA on CIPN and suggested a novel strategy for treating CIPN in 
      clinic.
FAU - Kuai, Cui-Ping
AU  - Kuai CP
AD  - Jiangsu Key Laboratory of TCM Evaluation and Translational Research, Department 
      of Pharmacology of Chinese Materia Medica, China Pharmaceutical University, 
      Nanjing, P. R. China.
AD  - Department of Pharmacology of Chinese Materia Medica, China Pharmaceutical 
      University, Nanjing, P. R. China.
FAU - Ju, Lin-Jie
AU  - Ju LJ
AD  - Jiangsu Key Laboratory of TCM Evaluation and Translational Research, Department 
      of Pharmacology of Chinese Materia Medica, China Pharmaceutical University, 
      Nanjing, P. R. China.
AD  - Department of Pharmacology of Chinese Materia Medica, China Pharmaceutical 
      University, Nanjing, P. R. China.
FAU - Hu, Pei-Pei
AU  - Hu PP
AD  - Jiangsu Key Laboratory of TCM Evaluation and Translational Research, Department 
      of Pharmacology of Chinese Materia Medica, China Pharmaceutical University, 
      Nanjing, P. R. China.
AD  - Department of Pharmacology of Chinese Materia Medica, China Pharmaceutical 
      University, Nanjing, P. R. China.
FAU - Huang, Fang
AU  - Huang F
AD  - Jiangsu Key Laboratory of TCM Evaluation and Translational Research, Department 
      of Pharmacology of Chinese Materia Medica, China Pharmaceutical University, 
      Nanjing, P. R. China.
AD  - Department of Pharmacology of Chinese Materia Medica, China Pharmaceutical 
      University, Nanjing, P. R. China.
LA  - eng
PT  - Journal Article
DEP - 20200305
PL  - Singapore
TA  - Am J Chin Med
JT  - The American journal of Chinese medicine
JID - 7901431
RN  - 0 (Alkaloids)
RN  - 0 (Analgesics)
RN  - 0 (TRPV Cation Channels)
RN  - 0 (Trpv1 protein, rat)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Alkaloids/isolation & purification/*pharmacology/*therapeutic use
MH  - *Analgesics
MH  - Animals
MH  - Cisplatin/*adverse effects
MH  - Corydalis/*chemistry
MH  - Neuralgia/*chemically induced/drug therapy/*genetics
MH  - *Phytotherapy
MH  - Rats
MH  - TRPV Cation Channels/*metabolism
OTO - NOTNLM
OT  - CSBTA
OT  - Cisplatin
OT  - Corydalis saxicola
OT  - IENF
OT  - Inflammation
OT  - TRPV1
OT  - p-p38
EDAT- 2020/03/07 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/03/07 06:00
PHST- 2020/03/07 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PHST- 2020/03/07 06:00 [entrez]
AID - 10.1142/S0192415X20500214 [doi]
PST - ppublish
SO  - Am J Chin Med. 2020;48(2):407-428. doi: 10.1142/S0192415X20500214. Epub 2020 Mar 
      5.